ATE195652T1 - Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung - Google Patents

Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung

Info

Publication number
ATE195652T1
ATE195652T1 AT94902475T AT94902475T ATE195652T1 AT E195652 T1 ATE195652 T1 AT E195652T1 AT 94902475 T AT94902475 T AT 94902475T AT 94902475 T AT94902475 T AT 94902475T AT E195652 T1 ATE195652 T1 AT E195652T1
Authority
AT
Austria
Prior art keywords
growth hormone
controlled release
microspheres
biological activity
polymeric
Prior art date
Application number
AT94902475T
Other languages
English (en)
Inventor
Henry Auer
M Amin Khan
Howard Bernstein
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25530460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE195652(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE195652T1 publication Critical patent/ATE195652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT94902475T 1992-12-02 1993-12-02 Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung ATE195652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98432392A 1992-12-02 1992-12-02
PCT/US1993/011621 WO1994012158A1 (en) 1992-12-02 1993-12-02 Controlled release growth hormone containing microspheres

Publications (1)

Publication Number Publication Date
ATE195652T1 true ATE195652T1 (de) 2000-09-15

Family

ID=25530460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94902475T ATE195652T1 (de) 1992-12-02 1993-12-02 Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung

Country Status (13)

Country Link
US (6) US5667808A (de)
EP (2) EP0674506B1 (de)
JP (1) JPH08503950A (de)
KR (1) KR19990022038A (de)
AT (1) ATE195652T1 (de)
AU (2) AU670168B2 (de)
CA (1) CA2150803C (de)
DE (1) DE69329295T2 (de)
DK (1) DK0674506T3 (de)
ES (1) ES2151541T3 (de)
GR (1) GR3034873T3 (de)
PT (1) PT674506E (de)
WO (1) WO1994012158A1 (de)

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
ES2151079T3 (es) * 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
RU2161502C2 (ru) * 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
EP1080718A1 (de) * 1995-06-07 2001-03-07 Alkermes Controlled Therapeutics, Inc. Zusammensetzung zur verzögerten Abgabe von menschlichem Wachstumshormon
AU705968B2 (en) * 1995-06-07 1999-06-03 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
KR100210509B1 (ko) * 1996-01-10 1999-07-15 성재갑 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
CA2241322C (en) 1996-03-28 2009-01-13 Takeda Chemical Industries, Ltd. Sustained-release preparation and its production
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0946169B1 (de) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
EP0949905B1 (de) 1996-12-20 2001-07-18 Alza Corporation Injizierbare depotgelzubereitung und herstellungsverfahren
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
ATE233097T1 (de) 1997-11-07 2003-03-15 Chiron Corp Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
US6168570B1 (en) * 1997-12-05 2001-01-02 Micrus Corporation Micro-strand cable with enhanced radiopacity
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
CN1301172A (zh) 1998-03-20 2001-06-27 武田药品工业株式会社 生理活性多肽的缓释制剂及其生产
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
DE60020677T2 (de) 1999-02-26 2006-05-04 Chiron Corp., Emeryville Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
US6451347B1 (en) 1999-03-01 2002-09-17 Alkermes Controlled Therapeutics, Inc. Method for purifying human growth hormone
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
HUP0201626A3 (en) * 1999-06-04 2004-05-28 Alza Corp Mountain View Implantable gel compositions and method of manufacture
EP1949890A3 (de) 1999-06-04 2011-05-18 ALZA Corporation Implantierbare Gelzusammensetzungen und Herstellungsverfahren dafür
US6586011B2 (en) 1999-06-10 2003-07-01 Southpac Trust International, Inc. Microencapsulated plasminogen activators
EP1953173B1 (de) 1999-06-15 2009-11-18 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US6310166B1 (en) 1999-08-12 2001-10-30 Closure Medical Corporation Sterilized cyanoacrylate solutions containing thickeners
FR2797784B1 (fr) * 1999-08-27 2001-11-30 Mainelab Procede d'encapsulation de matieres actives par coacervation de polymeres en solvant organique non-chlore
CN1222319C (zh) * 1999-09-16 2005-10-12 诺沃挪第克公司 用于体外受精的组合物
CN1384751A (zh) 1999-09-17 2002-12-11 武田药品工业株式会社 蛋白粉生产方法
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
US20040071715A1 (en) * 1999-12-15 2004-04-15 Schwendeman Steven P. Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
EP1897947B1 (de) 1999-12-23 2012-01-18 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
CN1425066B (zh) * 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US6821520B2 (en) * 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6328977B1 (en) 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
JP2003528149A (ja) * 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
IL152360A0 (en) 2000-04-19 2003-05-29 Genentech Inc Sustained release formulations
TWI290473B (en) * 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
KR100381382B1 (ko) * 2000-06-28 2003-04-23 한국과학기술원 지속적 약물조절방출이 가능한 생분해성 미립담체 및 그의제조방법
US6719970B1 (en) 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
TWI283182B (en) 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
KR100867392B1 (ko) * 2000-08-15 2008-11-06 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 마이크로입자
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
JP2004510730A (ja) 2000-10-06 2004-04-08 ヤゴテック　アーゲー 非経口的投与可能な制御放出微粒子調製物
SE517422C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
SE518008C2 (sv) * 2000-11-16 2002-08-13 Bioglan Ab Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
US20070142325A1 (en) * 2001-01-08 2007-06-21 Gustavsson Nils O Starch
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US7824700B2 (en) * 2001-02-23 2010-11-02 Genentech, Inc. Erodible polymers for injection
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US6887857B2 (en) * 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1397155B1 (de) 2001-06-21 2015-09-30 Genentech, Inc. Formulierung mit verzögerter freisetzung
PT1418890E (pt) * 2001-08-16 2008-06-09 Baxter Int Formulações de micropartículas à base de propulsor
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7105181B2 (en) 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
JP4837892B2 (ja) * 2001-11-01 2011-12-14 ネクター セラピューティクス 粉末バッチを製造する方法
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
JP2005519873A (ja) * 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
WO2003041684A2 (en) * 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
MXPA04005865A (es) * 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
EP1471891A4 (de) * 2002-02-08 2007-04-11 Alkermes Inc Zusammensetzungen auf polymerbasis mit verzögerter freisetzung
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
SE0201599D0 (sv) 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
WO2003085092A2 (en) * 2002-04-01 2003-10-16 Law Peter K Cellular transplantation for heart regeneration
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
CN1684663A (zh) * 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
US8252303B2 (en) * 2002-07-31 2012-08-28 Durect Corporation Injectable depot compositions and uses thereof
EP1581181B1 (de) * 2002-11-06 2008-12-24 ALZA Corporation Depot-formulierungen mit verzögerter freisetzung
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
DE10315538A1 (de) * 2003-04-04 2004-10-21 Siemens Ag Teilchen mit einer Membran
WO2004091658A1 (en) 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
EP1620072B1 (de) * 2003-05-01 2008-03-26 LTT Bio-Pharma Co., Ltd. Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
BRPI0410953A (pt) * 2003-05-30 2006-06-27 Alza Corp composições de depósito elastoméricas que podem ser implantadas, usos das mesmas e processo de produção
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
EP2093570A1 (de) 2003-06-06 2009-08-26 Genentech, Inc. Modulierung der Interaktion zwischen HGF-beta-Kette und c-Met
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
KR101137785B1 (ko) * 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20050048127A1 (en) * 2003-07-22 2005-03-03 Larry Brown Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
EP1673464A2 (de) * 2003-10-10 2006-06-28 Novo Nordisk A/S Konjugation von peptiden
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
FR2862541B1 (fr) * 2003-11-21 2007-04-20 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques
FR2862535B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US7309500B2 (en) * 2003-12-04 2007-12-18 The Board Of Trustees Of The University Of Illinois Microparticles
EP1692178A1 (de) 2003-12-11 2006-08-23 Genentech, Inc. Verfahren und produkt um c-met dimerisierung und aktivierung zu verhindern
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
KR101204286B1 (ko) 2004-03-30 2012-11-26 엔에스진 에이/에스 성장 인자 ＮｓＧ33의 치료학적 용도
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
CN1980974A (zh) * 2004-04-23 2007-06-13 安姆根有限公司 低分子量聚乳酸聚合物
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
AU2005244851B2 (en) * 2004-05-12 2010-08-26 Baxter Healthcare S.A. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
AU2005244840C1 (en) 2004-05-12 2012-05-10 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
AU2005244842B2 (en) 2004-05-12 2010-09-23 Baxter Healthcare S.A. Nucleic acid microspheres, production and delivery thereof
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
SI1786400T1 (sl) * 2004-08-12 2009-08-31 Quest Pharmaceutical Services Farmacevtski sestavki za dajanje biološko aktivnih spojin z nadzorovanim sproščanjem
KR101242543B1 (ko) 2004-10-27 2013-03-22 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법
US7748343B2 (en) 2004-11-22 2010-07-06 The Board Of Trustees Of The University Of Illinois Electrohydrodynamic spraying system
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006102659A2 (en) * 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
US20060260777A1 (en) * 2005-04-27 2006-11-23 Julia Rashba-Step Surface-modified microparticles and methods of forming and using the same
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
KR20140139618A (ko) 2005-06-21 2014-12-05 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1995321A2 (de) 2005-08-15 2008-11-26 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
CA2620903A1 (en) * 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
EP1962584A2 (de) 2005-11-21 2008-09-03 Genentech, Inc. Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
EP1976551A4 (de) * 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc Zusammensetzungen mit polykation-komplex-proteinkristallen und behandlungsverfahren damit
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2389946A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
ES2385261T3 (es) 2006-04-10 2012-07-20 Genentech, Inc. Moduladores de PDZ Disheveled
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
CN105168146A (zh) 2006-08-04 2015-12-23 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
EP2068845A2 (de) * 2006-10-06 2009-06-17 Baxter International Inc. Mikroverkapselungen mit oberflächenmodifizierten mikropartikeln sowie verfahren zu ihrer herstellung und verwendung
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
EP2157967B1 (de) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspensionsformulierungen insulinotroper peptide und ihre verwendung
US20080264641A1 (en) * 2007-04-30 2008-10-30 Slabaugh Billy F Blending Fracturing Gel
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
KR100845009B1 (ko) * 2007-08-07 2008-07-08 한국생명공학연구원 전하를 띠는 물질이 고착된 다공성 고분자 입자 및 그제조방법
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009117410A2 (en) * 2008-03-17 2009-09-24 Board Of Regents, The University Of Texas System Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques
KR20110038139A (ko) 2008-07-17 2011-04-13 메리얼 리미티드 폴리오르소에스테르 및 이의 제형의 안정성 강화 방법
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
EP2389160B1 (de) * 2009-01-23 2017-09-13 Evonik Corporation Kontinuierliches doppelemulsionsverfahren zur herstellung von mikroteilchen
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2423233B1 (de) 2009-04-22 2015-03-11 Alteogen, Inc Durch in-vivo-freisetzung stabilisiertes fusionsprotein mit erhöhter in-vivo-halbwertzeit sowie verfahren zur erhöhung der in-vivo-halbwertzeit damit
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
JP6016636B2 (ja) * 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
JP5937059B2 (ja) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma
JP5913326B2 (ja) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー，リミテッド モエシン断片の診断的および治療的使用
US9345764B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2013066866A1 (en) 2011-10-31 2013-05-10 Genentech, Inc. Antibody formulations
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
WO2013168167A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
EP3733694A1 (de) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
JP2022544549A (ja) 2019-08-12 2022-10-19 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
EP4048405A2 (de) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimäre cytokin-modifizierte antikörper und verfahren zu deren verwendung
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
CA3217865A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
KR20240006581A (ko) 2021-05-06 2024-01-15 호바 세라퓨틱스 에이피에스 화학요법-유도된 신경병성 통증의 예방 및 치료
CA3239550A1 (en) 2021-12-10 2023-06-15 Kenneth Petersen Treatment of nociceptive pain

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5122367A (en) * 1989-03-31 1992-06-16 Massachusetts Institute Of Technology Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
WO1992011844A1 (en) * 1991-01-03 1992-07-23 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5176907A (en) * 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
ATE154240T1 (de) * 1992-03-12 1997-06-15 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
PT644771E (pt) * 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
AUPM784894A0 (en) * 1994-09-02 1994-09-29 Murchie, Barry Joseph Baby's breathing aid
ES2151079T3 (es) * 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.

Also Published As

Publication number Publication date
US5654010A (en) 1997-08-05
DK0674506T3 (da) 2001-01-08
AU670168B2 (en) 1996-07-04
CA2150803C (en) 2006-01-31
EP1013270A2 (de) 2000-06-28
DE69329295D1 (de) 2000-09-28
JPH08503950A (ja) 1996-04-30
CA2150803A1 (en) 1994-06-09
DE69329295T2 (de) 2001-03-15
ES2151541T3 (es) 2001-01-01
AU5683594A (en) 1994-06-22
US6051259A (en) 2000-04-18
US5891478A (en) 1999-04-06
KR19990022038A (ko) 1999-03-25
AU694378B2 (en) 1998-07-16
AU6802996A (en) 1996-12-19
PT674506E (pt) 2001-01-31
EP0674506B1 (de) 2000-08-23
WO1994012158A1 (en) 1994-06-09
GR3034873T3 (en) 2001-02-28
US5667808A (en) 1997-09-16
EP0674506A1 (de) 1995-10-04
US20030211153A1 (en) 2003-11-13
EP1013270A3 (de) 2001-03-28
US6500448B1 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
ATE195652T1 (de) Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
ATE154240T1 (de) Acth enthaltende mikrokugeln mit gesteuerter abgabe
DK0615438T3 (da) En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel
ES2030026T3 (es) Sistema terapeutico transdermal, su aplicacion y procedimiento para su fabricacion.
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
ATE147621T1 (de) Wirkstoffabgabevorrichtung mit gesteuerter freigabe enthaltend eine polymermatrix und einen weichmacher
ATE113607T1 (de) Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
ATE203913T1 (de) Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
DE69431800D1 (de) Arzneiverabreichungssystem
BR7707215A (pt) Copolimeros biologicamente ativos;composicao de revestimento liquida para controlar o estabelecimento e crescimento de organismos infestantes
DK0873134T3 (da) Langvarig frigørelsesformulering omfattende bovin væksthormon frigørende faktor
Barrett Adult body temperatures and the development of endothermy in the puffin Fratercula arctica, razorbill, Alca torda and guillemot Uria aalge.
ATE187077T1 (de) Wässrige zubereitung mit verzögerter wirkstofffreigabe
HUT47377A (en) Insecticide-granulate with increased biological effect containing as active substance carbofuran
DE68902071D1 (de) Human-wachstumshormon-derivat.
Trukhan et al. On the state of the population of anopheline mosquitoes on the territory of the Byelorussia.
ES2073454T3 (es) Soporte para moleculas biologicamente activas o a su vez biologicamente activo, su procedimiento de preparacion y su aplicacion en biologia.
Sivovolova et al. The reproductive activity of Trichinella spiralis in the early stages of cultivation on artificial nutrient media
Weiguo CONTRAST RESEARCHES ON HATCHING THE SPAWN OF RANA SPINOSA
李邦河 et al. SKIES AND MONADS
TH13365A (th) สูตรผสมสารที่ปลดปล่อยอย่างต่อเนื่องออกไปและสามารถฉีดได้และวิธีต่างๆ
TH13365EX (th) สูตรผสมสารที่ปลดปล่อยอย่างต่อเนื่องออกไปและสามารถฉีดได้และวิธีต่างๆ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee